Syphilis Clinical Trial
Official title:
Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis. Do Low Serum Penicillin Levels Correlate With Treatment Failure?
Verified date | April 2018 |
Source | Ottawa Hospital Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Syphilis is a sexually transmitted infection that causes genital sores and rash, but in some
circumstances may result in more severe and unexpected symptoms. These severe symptoms could
include eye infections, meningitis (infection of the membranes covering the brain and spinal
cord), and liver infection. If not properly treated, syphilis can also lead to heart problems
and dementia (a decline in reasoning, memory and other mental abilities) years down the road.
There has been an increase in the number of reported cases of syphilis in North America,
Europe, and Australia over the past decade. The number of new syphilis infections in Canada
has increased roughly 10-fold over the past 10 years.
Since 1943, the antibiotic penicillin has been used to treat syphilis; however, very little
information has been gathered to determine the proper dose of penicillin or appropriate
duration of treatment. Added to this, several studies have shown that the recommended dose of
penicillin fails to cure syphilis in 20-30% of patients. Since the number of people infected
with syphilis is increasing, and since syphilis has the potential to cause serious disease,
the investigators need better information on how to treat syphilis effectively.
This study aims to determine whether the current dose of penicillin recommended to treat
syphilis is sufficient to cure the infection. Specifically the investigators will try to
determine whether the amount of penicillin in your blood 3 and 7 days after receiving
treatment for syphilis is sufficient to cure the infection as demonstrated by a blood test 6
or 12 months from now. This study is a multi-centered trial based in Ottawa but with centers
recruiting both in Montreal and Toronto. A total of 120 participants with syphilis will be
recruited into this study. The treatment you will receive for syphilis in this study does not
differ from that you would receive normally; the investigators are only observing the levels
of penicillin in your blood and relating them with the outcome of treatment.
Status | Terminated |
Enrollment | 25 |
Est. completion date | November 10, 2016 |
Est. primary completion date | November 10, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Participants must meet all of the following criteria to be considered eligible for entry into the study: 1. At least 18 years of age 2. Presenting with clinical signs of either primary or secondary syphilis; or with early latent syphilis and documented negative serology within the past 12 months. 3. Positive syphilis serology (reactive CMIA and TP-PA) with a defined RPR titer at the time of diagnosis and enrolment 4. Able to provide informed consent 5. Able to communicate in either English of French 6. Able to return for follow-up Exclusion Criteria: Participants are not eligible to participate in the study if any of the following conditions are met: 1. Diagnosis of late latent syphilis, tertiary syphilis, or syphilis of unknown duration 2. Allergy to penicillin 3. Diagnosis of neurosyphilis requiring treatment with intravenous penicillin 4. Treatment with doxycycline or ceftriaxone 5. Treatment with more than one intramuscular dose of benzathine penicillin G 6. Treatment with any antibiotics within the 6 weeks prior to enrolment 7. Pregnant or breastfeeding 8. Any immune modulating therapy 9. Patient is unable or unwilling to return for blood sampling at 3 and 7 days post treatment |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Sexual Health Clinic/GayZone | Ottawa | Ontario |
Canada | The Ottawa Hospital | Ottawa | Ontario |
Canada | Toronto General Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Ottawa Hospital Research Institute | CIHR Canadian HIV Trials Network |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Penicillin and Treatment Failure | To determine if serum penicillin concentrations measured at days 3 and 7 post-treatment differ between those who achieve successful treatment of infectious syphilis versus those who experience treatment failure. | 6 months post-treatment | |
Secondary | HIV and Treatment Failure | To determine if serum penicillin levels and treatment failures differ between HIV-positive and HIV-negative individuals. | 6 months post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03660488 -
Cefixime for Alternative Syphilis Treatment
|
Phase 2 | |
Recruiting |
NCT05548426 -
Linezolid for Syphilis Pilot Study
|
Phase 2 | |
Completed |
NCT02191527 -
Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique
|
N/A | |
Completed |
NCT01439503 -
Safer Sex Program for Young African-American Men
|
Phase 2 | |
Completed |
NCT02257658 -
Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM
|
N/A | |
Completed |
NCT02611765 -
Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
|
Phase 4 | |
Not yet recruiting |
NCT06428643 -
A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities
|
N/A | |
Completed |
NCT03709862 -
Global Syphilis Sequencing
|
||
Completed |
NCT03637660 -
Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection
|
Phase 4 | |
Active, not recruiting |
NCT03310424 -
Transcriptomic and Next Generation Sequencing Approaches to Infection With Treponema Pallidum
|
||
Completed |
NCT00207506 -
Lay Health Advisors for Sexually Transmitted Disease Prevention
|
Phase 1/Phase 2 | |
Completed |
NCT00213018 -
Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission
|
Phase 2 | |
Recruiting |
NCT06059443 -
mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention
|
N/A | |
Completed |
NCT04480749 -
Syphilis Self-testing to Expand Test Uptake Among Men Who Have Sex With Men (SST)
|
Phase 4 | |
Not yet recruiting |
NCT06058286 -
MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in Indonesia
|
N/A | |
Active, not recruiting |
NCT03980223 -
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
|
Phase 4 | |
Completed |
NCT01465607 -
Implementation of an Efficacious Intervention for High Risk Women in Mexico
|
N/A | |
Completed |
NCT00553111 -
Video Tool to Promote Knowledge of Syphilis as Facilitator of HIV Transmission
|
N/A | |
Active, not recruiting |
NCT06367621 -
Retrospective Study of iStatis Syphilis Ab Test (POC)
|
||
Completed |
NCT02445846 -
Dual Rapid HIV & Syphilis Tests in Zambia
|
N/A |